Arrevus
Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.
Conquering antibiotic resistance by targeting critical diseases with innovative DPCs.
Arrevus is a biotechnology and pharmaceutical startup, founded in 2015, with a mission to address antibiotic resistance in critical diseases. The company's focus lies in developing Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs) for diseases where antibiotic resistance has significant clinical implications and limited treatment options. With their slogan "Conquering antibiotic resistance by targeting critical diseases with innovative DPCs," Arrevus aims to combat the impact of antibacterial resistance on patient health outcomes. Their last investment of $800.00K came in the form of a grant from the U.S. Department of Defense on 29 May 2020. Arrevus stands out for its dedication to addressing a pressing issue in the medical field and its strategic approach to drug development, positioning it as an impactful player in the fight against antibiotic resistance.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $800.00K | 1 | U.S. Department of Defense | 29 May 2020 |
| Debt Financing | $250.00K | 1 | North Carolina Biotechnology Center | 16 Oct 2019 |
| Venture Round | $1.00M | - | 26 May 2017 |
No recent news or press coverage available for Arrevus.
We care about your data, and we'd love to use cookies make your experience better.